MAINTENANCE OF QUALITY OF LIFE IMPROVEMENT IN A PHASE 3 STUDY OF TOFACITINIB FOR PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS

被引：1
|
作者：
Panes, Julian
Rubin, David T.
Vermeire, Severine
Lindsay, James O.
Sands, Bruce E.
Su, Chinyu
Friedman, Gary
Zhang, Haiying
Kayhan, Cem
Manuchehri, Alireza
Healey, Paul J.
机构：
来源：
GASTROENTEROLOGY | 2017年 / 152卷 / 05期
关键词：
D O I：
10.1016/S0016-5085(17)32148-0
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
Su1932
引用
收藏
页码：S601 / S602
页数：3
相关论文
共 50 条
  • [31] HISTOLOGIC REMISSION AND MUCOSAL HEALING IN A PHASE 2 STUDY OF MIRIKIZUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
    Pai, Rish
    Canavan, James
    Tuttle, Jay
    Durante, Michael
    Arora, Vipin
    Milch, Catherine
    Harpaz, Noam
    D'Haens, Geert R.
    Sands, Bruce E.
    Sandborn, William J.
    [J]. GASTROENTEROLOGY, 2020, 158 (06) : S1187 - S1187
  • [32] Vedolizumab for the Treatment of Moderately to Severely Active Ulcerative Colitis
    Dulai, Parambir S.
    Mosli, Mahmoud
    Khanna, Reena
    Levesque, Barrett G.
    Sandborn, William J.
    Feagan, Brian G.
    [J]. PHARMACOTHERAPY, 2015, 35 (04): : 412 - 423
  • [33] A MATCHING-ADJUSTED INDIRECT COMPARISON OF FILGOTINIB VERSUS TOFACITINIB FOR MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
    Lu, X.
    Gray, E.
    Xin, Y.
    Zhou, J.
    Jairath, V
    Lindsay, J. O.
    [J]. VALUE IN HEALTH, 2022, 25 (07) : S321 - S321
  • [34] Early Symptomatic Improvement With Guselkumab Induction Treatment in Moderately to Severely Active Ulcerative Colitis: Results From the Phase 3 QUASAR Induction Study
    Lichtenstein, Gary R.
    Dignass, Axel
    Rubin, David T.
    Yarandi, Shadi
    Huang, Kuan-Hsiang G.
    Germinaro, Matthew
    Miao, Ye
    Zhang, Hongyan
    Kierkus, Jaroslaw
    Seidler, Ursula
    Maemoto, Atsuo
    Allegretti, Jessica R.
    Bressler, Brian
    Peyrin-Biroulet, Laurent
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2023, 118 (10): : S623 - S624
  • [35] Erratum to: Four-year maintenance treatment with adalimumab in Japanese patients with moderately to severely active ulcerative colitis
    Yasuo Suzuki
    Satoshi Motoya
    Hiroyuki Hanai
    Toshifumi Hibi
    Shiro Nakamura
    Andreas Lazar
    Anne Martin Robinson
    Martha Skup
    Nael Mohamed Mostafa
    Bidan Huang
    Roopal Thakkar
    Mamoru Watanabe
    [J]. Journal of Gastroenterology, 2017, 52 : 1079 - 1079
  • [36] Adalimumab induction therapy improves health-related quality of life in patients with moderately to severely active ulcerative colitis.
    Sandborn, W.
    Reinisch, W.
    Thakkar, R.
    Lazar, A.
    Huang, B.
    Mulani, P.
    Chao, J.
    [J]. INFLAMMATORY BOWEL DISEASES, 2011, 17 : S60 - S61
  • [37] Corticosteroid-Sparing Effect in Patients With Moderately to Severely Active Ulcerative Colitis Treated With Mirikizumab Maintenance Therapy
    Laharie, David
    Siegel, Corey A.
    Samaan, Karen
    Fischer, Deborah
    Morris, Nathan
    Redondo, Isabel
    Dulai, Parambir S.
    Jairath, Vipul
    Gisbert, Javier P.
    Matsuoka, Katsuyoshi
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2023, 118 (10): : S635 - S635
  • [38] Four-year maintenance treatment with adalimumab in Japanese patients with moderately to severely active ulcerative colitis (2017)
    Suzuki, Yasuo
    Motoya, Satoshi
    Hanai, Hiroyuki
    Hibi, Toshifumi
    Nakamura, Shiro
    Lazar, Andreas
    Robinson, Anne Martin
    Skup, Martha
    Mostafa, Nael Mohamed
    Huang, Bidan
    Thakkar, Roopal
    Watanabe, Mamoru
    [J]. JOURNAL OF GASTROENTEROLOGY, 2017, 52 (09) : 1079 - 1079
  • [39] CORTICOSTEROID-SPARING EFFECT IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS TREATED WITH MIRIKIZUMAB MAINTENANCE THERAPY
    Laharie, D.
    Siegel, C. A.
    Samaan, K.
    Fisher, D. A.
    Morris, N.
    Redondo, I.
    Dulai, P. S.
    Jairath, V.
    Gisbert, J. P.
    Matsuoka, K.
    Orlando, A.
    [J]. DIGESTIVE AND LIVER DISEASE, 2024, 56 : S163 - S164
  • [40] REDUCTION IN INFLAMMATORY BIOMARKERS IN A PHASE 2 STUDY OF MIRIKIZUMAB IN THE TREATMENT OF PATIENTS WITH MODERATELY-TO-SEVERELY ACTIVE ULCERATIVE COLITIS
    Sandborn, William J.
    Sands, Bruce E.
    Kobayashi, Taku
    Tuttle, Jay
    Schmitz, Jochen
    Durante, Michael
    Higgs, Richard E.
    Canavan, James
    Siegel, Robert
    Ferrante, Marc
    [J]. GASTROENTEROLOGY, 2019, 156 (06) : S1094 - S1095
12345